The drug anakinra, intended to treat juvenile rheumatoid arthritis, appears also to be a useful treatment for Type 2 diabetes, according to a study published today. The interleukin-1-receptor antagonist showed in a study to reduce long-term levels of glucose in the blood and improve insulin production when given in daily injections.

Full Story:

Related Summaries